Search Results

You are looking at 1 - 4 of 4 items for :

  • Editor's Choice x
Clear All
Open access

T P Parikh, B Stolze, Y Ozarda, J Jonklaas, K Welsh, L Masika, M Hill, A DeCherney and S J Soldin

of high-performance liquid chromatography (HPLC) in conjunction with tandem mass spectrometry (MS) is increasingly becoming the method of choice for clinical testing of hormone levels ( 5 , 6 , 15 , 16 , 17 ). Given its high sensitivity

Open access

Marcus Quinkler, Bertil Ekman, Claudio Marelli, Sharif Uddin, Pierre Zelissen, Robert D Murray and on behalf of the EU-AIR Investigators

were followed during the course of routine clinical practice for the active duration of the registry. All medical care decisions, including those relating to treatment choice, are entirely at the discretion of the patient and registry physician. Patient

Open access

Simon Chang, Christian Fynbo Christiansen, Anders Bojesen, Svend Juul, Anna-Marie B Münster and Claus H Gravholt

-treatment could be by choice, we show that the majority of men with KS not being offered testosterone treatment indeed had laboratory findings suggestive of hypogonadism indicating a lapse in clinical care. There is a need to further explore the traits of those

Open access

Michael Ulm, Arvind V Ramesh, Keely M McNamara, Suriyan Ponnusamy, Hironobu Sasano and Ramesh Narayanan

carcinomas, HER2-directed therapy (either through HER2-directed antibodies or downstream tyrosine kinase inhibitors) is typically the avenue of choice. Currently, there are four FDA-approved targeted therapies that inhibit this pathway. The first in this